Follow the people · Insider
Pierre Sargis Sayad
Pierre Sargis Sayad files insider transactions with the SEC as a chief medical officer of Fennec Pharmaceuticals (FENC). We hold 1 disclosed purchase or sale filed since 13 November 2024, 1 of them in the last 90 days.
- Files forFENC
- Disclosed buys and sells1 in all, 1 in the last 90 days
- Last disclosure31 August 2026
Positions held
1 post we hold — a term names its own dates; a run of filings only says when they filed- Filed 13 November 2024 — 31 August 2026Chief Medical Officer · Fennec Pharmaceuticals (FENC)12 Form 4 lines · source: SEC Form 4
Everything they disclosed
12 entries, newest first — one per disclosure report, one per Form 4 line- was granted 168 shares of Fennec PharmaceuticalsSEC Form 431 August 2026Common Shares · traded 31 August 2026 · filed 31 August 2026
- ▼ sold on the open market 12,000 shares of Fennec PharmaceuticalsSEC Form 431 August 2026Common Shares · traded 31 August 2026 · filed 31 August 2026
- was granted 168 shares of Fennec PharmaceuticalsSEC Form 43 August 2026Common Shares · traded 31 July 2026 · filed 3 August 2026
- was granted 168 shares of Fennec PharmaceuticalsSEC Form 41 July 2026Common Shares · traded 30 June 2026 · filed 1 July 2026
- was granted 168 shares of Fennec PharmaceuticalsSEC Form 41 June 2026Common Shares · traded 31 May 2026 · filed 1 June 2026
- exercised options over 168 shares of Fennec PharmaceuticalsSEC Form 41 May 2026Common Shares · traded 30 April 2026 · filed 1 May 2026
- exercised options over 18,456 shares of Fennec PharmaceuticalsSEC Form 42 April 2026Common Shares · traded 31 March 2026 · filed 2 April 2026
- exercised options over 171 shares of Fennec PharmaceuticalsSEC Form 42 April 2026Common shares · traded 31 March 2026 · filed 2 April 2026
- exercised options over 2,052 shares of Fennec PharmaceuticalsSEC Form 42 April 2026Common shares · traded 28 March 2026 · filed 2 April 2026
- was granted 120,000 shares of Fennec Pharmaceuticals (a derivative holding)SEC Form 42 April 2026Stock Options · traded 31 March 2026 · filed 2 April 2026
- was granted 10,000 shares of Fennec Pharmaceuticals (a derivative holding)SEC Form 43 April 2025Restricted Share Unit · traded 28 March 2025 · filed 3 April 2025
- was granted 150,000 shares of Fennec Pharmaceuticals (a derivative holding)SEC Form 413 November 2024Stock Options · traded 13 November 2024 · filed 13 November 2024
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.